Objective:To systematically review the qualitative research on the care experience of caregivers of palliative care for minors, in order to provide a reference for formulating a care plan that is more in line with the needs of palliative care for minors and their families.Methods:The Cochrane Library, Australia Joanna Briggs Institute Evidence-based Health Care Center Library, Embase, PubMed and Web of Science, CINAHL, China National Knowledge Infrastructure, Wanfang Database, VIP Database and China Biology Medicine Disc were searched by computer for literature on qualitative research on care experience of underage hospice care caregivers from the establishment of the database to December 30, 2023.Results:A total of 11 articles were included and 70 research results were extracted, which were summarized into 7 new categories and formed 2 integrated results: professional caregivers and relative caregivers had multiple care burden, and need multiple care support; professional caregivers and relative caregivers can shoulder the care responsibility of children together, actively respond to the difficulties in care, gain personal care experience and growth.Conclusions:Hospice care for minors has its own characteristics, and caregivers have various care burdens and needs. Special attention should be paid to the emotional experience and care demands of caregivers, and targeted support and protection should be provided to promote the construction of hospice care team for minors in China and improve the level of hospice care for minors in China.

Objective:To analyze whether the application of growth hormone (GH) in the frozen-thawed embryo transfer (FET) cycle can improve the pregnancy outcome of patients.Methods:The retrospective cohort study including 1042 FET cycles was carried out between January 2015 to July 2018 in Reproductive Medicine Center,the Fourth Hospital of Hebei Medical University. According to medication before transfer, all patients were divided into GH group (group A ) and no GH group (group B). The pregnancy outcomes were compared between the two groups in aged patients (≥35 years), polycystic ovary syndrome (PCOS) patients and repeated implantation failure (RIF) patients.Results:In group A, the maternal age [(31.1±4.5) years old] and the clinical pregnancy rate [67.1% (114/170)] were higher than those in group B [(30.1±4.4) years old, 57.5% (501/872)]( P=0.010, P=0.020). There were no significant differences in the implantation rate, the clinical pregnancy rate, the abortion rate and the live birth rate between group A and group B in aged patients (all P>0.05). In PCOS patients, the live birth rate in group A [65.8% (25/38)] was significantly higher than that in group B [42.3% (96/227)] ( P=0.007). In the RIF patients, the implantation rate [37.3% (57/153)], the clinical pregnancy rate [50.5% (46/91)] and the live birth rate [37.4% (34/91)] in group A were significantly higher than those in group B [23.0% (115/501), 29.1% (92/316), 21.8% (69/316)] ( P<0.001, P<0.001, P=0.003). Conclusion:For the aged patients, adding GH could not improve pregnancy outcomes. The application of GH in PCOS patients could increase the live birth rate. For the RIF patients, the application of GH could increase the implantation rate, the clinical pregnancy rate and the live birth rate.

Objective:To analyze whether the application of growth hormone (GH) in the frozen-thawed embryo transfer (FET) cycle can improve the pregnancy outcome of patients.Methods:The retrospective cohort study including 1042 FET cycles was carried out between January 2015 to July 2018 in Reproductive Medicine Center,the Fourth Hospital of Hebei Medical University. According to medication before transfer, all patients were divided into GH group (group A ) and no GH group (group B). The pregnancy outcomes were compared between the two groups in aged patients (≥35 years), polycystic ovary syndrome (PCOS) patients and repeated implantation failure (RIF) patients.Results:In group A, the maternal age [(31.1±4.5) years old] and the clinical pregnancy rate [67.1% (114/170)] were higher than those in group B [(30.1±4.4) years old, 57.5% (501/872)]( P=0.010, P=0.020). There were no significant differences in the implantation rate, the clinical pregnancy rate, the abortion rate and the live birth rate between group A and group B in aged patients (all P>0.05). In PCOS patients, the live birth rate in group A [65.8% (25/38)] was significantly higher than that in group B [42.3% (96/227)] ( P=0.007). In the RIF patients, the implantation rate [37.3% (57/153)], the clinical pregnancy rate [50.5% (46/91)] and the live birth rate [37.4% (34/91)] in group A were significantly higher than those in group B [23.0% (115/501), 29.1% (92/316), 21.8% (69/316)] ( P<0.001, P<0.001, P=0.003). Conclusion:For the aged patients, adding GH could not improve pregnancy outcomes. The application of GH in PCOS patients could increase the live birth rate. For the RIF patients, the application of GH could increase the implantation rate, the clinical pregnancy rate and the live birth rate.

Objective:To explore the clinical outcomes of luteal phase stimulation (LPS) for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment in patients with poor ovarian response (POR). Methods:Retrospective analysis was conducted on the clinical, laboratory data and clinical pregnancy outcome of frozen-thawed embryo transfer of 134 POR patients using LPS protocol for IVF/ICSI treatment in Reproductive Medical Center of the Fourth Hospital of Hebei Medical University from June 2013 to December 2018.Results:Totally 142 IVF/ICSI cycles were completed in 134 POR patients. About 5.63% (8/142) cycles cancelled due to unsuitable follicle, 7.75% (11/142) were failed to obtain oocyte and 37.32% (53/142) had unsuitable embryos for freezing, the total cancellation rate reached 50.70%. The duration of human menopausal gonadotropin (hMG) used was (10.04±3.51) d and the used dosage was (2 330.00±890.48) IU. In 24.64% (35/142) cycles, progesterone decreased to less than 1 μg/L on the trigger day. The number of oocytes retrieved, M II oocytes, two pronucleus (2PN), available embryos, high-quality embryos were 3.13±2.60, 2.98±2.25, 2.17±1.69, 2.04±1.53, 1(0.2), respectively. The rates of oocytes retrieved, M II oocytes, 2PN, available embryos, high-quality embryos were 76.04% (419/551), 86.63% (363/419), 69.97% (254/363), 91.34% (232/254) and 46.06% (117/254), respectively. Before June 2016, high-quality embryos were frozen, and poor-quality embryos were cultured, the blastocyst formation rate was 15.22% (7/46). After June 2016, all available embryos were cultured, the blastocyst formation rate was 41.98% (55/131). In the following frozen-thawed embryo transfer cycles, the clinical pregnancy rate per transfer cycle was 41.67% (25/60), the abortion rate was 44.00% (11/25), and the live birth rate was 23.33% (14/60). Conclusion:The cancellation rate of LPS protocol was high in POR patients. If there were frozen embryos for transfer, the clinical pregnancy rate would be satisfied, but the abortion rate was high.

Objective:To explore the clinical outcomes of luteal phase stimulation (LPS) for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment in patients with poor ovarian response (POR). Methods:Retrospective analysis was conducted on the clinical, laboratory data and clinical pregnancy outcome of frozen-thawed embryo transfer of 134 POR patients using LPS protocol for IVF/ICSI treatment in Reproductive Medical Center of the Fourth Hospital of Hebei Medical University from June 2013 to December 2018.Results:Totally 142 IVF/ICSI cycles were completed in 134 POR patients. About 5.63% (8/142) cycles cancelled due to unsuitable follicle, 7.75% (11/142) were failed to obtain oocyte and 37.32% (53/142) had unsuitable embryos for freezing, the total cancellation rate reached 50.70%. The duration of human menopausal gonadotropin (hMG) used was (10.04±3.51) d and the used dosage was (2 330.00±890.48) IU. In 24.64% (35/142) cycles, progesterone decreased to less than 1 μg/L on the trigger day. The number of oocytes retrieved, M II oocytes, two pronucleus (2PN), available embryos, high-quality embryos were 3.13±2.60, 2.98±2.25, 2.17±1.69, 2.04±1.53, 1(0.2), respectively. The rates of oocytes retrieved, M II oocytes, 2PN, available embryos, high-quality embryos were 76.04% (419/551), 86.63% (363/419), 69.97% (254/363), 91.34% (232/254) and 46.06% (117/254), respectively. Before June 2016, high-quality embryos were frozen, and poor-quality embryos were cultured, the blastocyst formation rate was 15.22% (7/46). After June 2016, all available embryos were cultured, the blastocyst formation rate was 41.98% (55/131). In the following frozen-thawed embryo transfer cycles, the clinical pregnancy rate per transfer cycle was 41.67% (25/60), the abortion rate was 44.00% (11/25), and the live birth rate was 23.33% (14/60). Conclusion:The cancellation rate of LPS protocol was high in POR patients. If there were frozen embryos for transfer, the clinical pregnancy rate would be satisfied, but the abortion rate was high.